Engineered exosomes targeting MYC reverse the proneural-mesenchymal transition and extend survival of glioblastoma
Extracellular Vesicle · 2022
DOI: 10.1016/j.vesic.2022.100014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Extracellular Vesicle, 2022. Verfasst von Amanda R Haltom und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Musella Foundation For Brain Tumor Research and Information, National Cancer Institute.
Abstract (Originalsprache)
Dysregulated Myc signaling is a key oncogenic pathway in glioblastoma multiforme (GBM). Yet, effective therapeutic targeting of Myc continues to be challenging. Here, we demonstrate that exosomes generated from human bone marrow mesenchymal stem cells (MSCs) engineered to encapsulate siRNAs targeting Myc (iExo-Myc) localize to orthotopic GBM tumors in mice. Treatment of late stage GBM tumors with iExo-Myc inhibits proliferation and angiogenesis, suppresses tumor growth, and extends survival. Transcriptional profiling of tumors reveals that the mesenchymal transition and estrogen receptor signaling pathways are impacted by Myc inhibition. Single nuclei RNA sequencing (snRNA-seq) shows that iExo-Myc treatment induces transcriptional repression of multiple growth factor and interleukin signaling pathways, triggering a mesenchymal to proneural transition and shifting the cellular landscape of the tumor. These data confirm that Myc is an effective anti-glioma target and that iExo-Myc offers a feasible, readily translational strategy to inhibit challenging oncogene targets for the treatment of brain tumors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Bioengineering, Rice University, Houston, TX.
- Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL.
- Feinberg School of Medicine & Kellogg School of Management, Northwestern University, Chicago, IL.
- James P. Allison Institute at MD Anderson, Houston, TX.
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.
Förderung
- NCI NIH HHS
- Musella Foundation For Brain Tumor Research and Information
- National Cancer Institute
- University of Texas MD Anderson Cancer Center
- National Institutes of Health
Zitieren
APA
Haltom, A. R., Hassen, W. E., Hensel, J., Kim, J., Sugimoto, H., Li, B., McAndrews, K. M., Conner, M. R., Kirtley, M. L., Luo, X., Xie, B., Volpert, O. V., Olalekan, S., Maltsev, N., Basu, A., LeBleu, V. S., & Kalluri, R. (2022). Engineered exosomes targeting MYC reverse the proneural-mesenchymal transition and extend survival of glioblastoma. Extracellular Vesicle. https://doi.org/10.1016/j.vesic.2022.100014
Vancouver
Haltom AR, Hassen WE, Hensel J, Kim J, Sugimoto H, Li B, et al. Engineered exosomes targeting MYC reverse the proneural-mesenchymal transition and extend survival of glioblastoma. Extracellular Vesicle. 2022. doi:10.1016/j.vesic.2022.100014
BibTeX
@article{Haltom2022,
author = {Haltom, Amanda R and Hassen, Wafa E and Hensel, Janine and Kim, Jiha and Sugimoto, Hikaru and Li, Bingrui and McAndrews, Kathleen M and Conner, Meagan R and Kirtley, Michelle L and Luo, Xin and Xie, Bingqing and Volpert, Olga V and Olalekan, Susan and Maltsev, Natalia and Basu, Anindita and LeBleu, Valerie S and Kalluri, Raghu},
title = {Engineered exosomes targeting MYC reverse the proneural-mesenchymal transition and extend survival of glioblastoma},
journal = {Extracellular Vesicle},
year = {2022},
doi = {10.1016/j.vesic.2022.100014}
}
EUVIMED